Recently licensed: A company has partnered with us to develop a new pain treatment technology that blocks CCL17 expression.
1 Minute read
Researchers have identified the CCL17 cytokine as a target for monoclonal antibody inhibition of the GM-CSF-driven pain pathway. It has the potential to improve pain treatments for chronic conditions.
The global analgesic market is set to grow to more than $US26 Billion by 2022. An increase in ageing populations is in part fuelling this growth.
Analgesics treat common inflammatory conditions such as arthritis but often with multiple adverse side effects. A need exists to create new agents with fewer side effects, lower risk of dependence and less drug resistance for the treatment of rheumatoid arthritis and other diseases.
Proof of concept has been shown in in vitro and in vivo models of CCL17 in inflammatory conditions. The University filed a patent application on 2 September 2014. This claimed a method of pain treatment by blocking CCL17 expression.
First published on 11 November 2020.
Share this article
Research commercialisation opportunitiesResearch Innovation and Commercialisation
Ultra-thin single crystal diamond membrane
Partner with us to develop the fabrication method for single crystal diamond membranes. Explore licensing and/or co-development opportunities.
Discover ways to create impact from your research through commercialisation with the right support, funding and advice.
Fast battery charging
This groundbreaking optimised battery charging technology reduces charging times by over 60 per cent and is poised to flip the lithium battery industry on its head.
Partner with us to speed up the adoption of the multispectral plasmonic pixel. Talk to us about licensing or direct investment.